Published in Curr Opin Neurol on December 01, 2007
Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol (2010) 1.40
Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. NMR Biomed (2011) 1.30
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol (2010) 1.10
Targeted therapies for malignant glioma: progress and potential. BioDrugs (2009) 0.97
Direct inhibition of myosin II effectively blocks glioma invasion in the presence of multiple motogens. Mol Biol Cell (2012) 0.97
YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Mol Cancer Ther (2013) 0.91
Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells. J Transl Med (2009) 0.89
Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM. Neuro Oncol (2011) 0.84
Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds. Curr Neuropharmacol (2016) 0.82
ID1 regulates U87 human cell proliferation and invasion. Oncol Lett (2013) 0.80
Editorial: what is new in the treatment of gliomas? Curr Opin Neurol (2007) 0.80
Increased expression of glutamate transporter GLT-1 in peritumoral tissue associated with prolonged survival and decreases in tumor growth in a rat model of experimental malignant glioma. J Neurosurg (2013) 0.77
Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments. Br J Radiol (2011) 0.75
The role of myosin II in glioma invasion: A mathematical model. PLoS One (2017) 0.75
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32
Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol (2012) 4.27
A multigene predictor of outcome in glioblastoma. Neuro Oncol (2009) 3.57
Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol (2007) 2.93
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46
Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys (2011) 2.18
Treatment recommendations for anaplastic oligodendrogliomas that are codeleted. Oncology (Williston Park) (2013) 2.04
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol (2004) 2.03
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol (2010) 1.99
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol (2011) 1.92
Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res (2002) 1.82
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol (2009) 1.69
Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res (2006) 1.67
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol (2009) 1.66
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol (2013) 1.63
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol (2013) 1.62
Cerebral radiation necrosis. Neurologist (2003) 1.50
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol (2011) 1.50
A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol (2012) 1.44
Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol (2011) 1.42
Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg (2008) 1.37
The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer (2005) 1.34
Bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 1.29
Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev (2008) 1.28
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol (2012) 1.27
Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. Clin Cancer Res (2008) 1.25
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol (2006) 1.25
Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. J Clin Oncol (2014) 1.24
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol (2008) 1.23
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol (2009) 1.21
Anaplastic astrocytoma: diagnosis, prognosis, and management. Semin Oncol (2004) 1.19
Atypical teratoid/rhabdoid tumors in adults: a case report and treatment-focused review. J Clin Med Res (2011) 1.18
Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. Neuro Oncol (2010) 1.18
Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol (2014) 1.17
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol (2005) 1.16
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2013) 1.15
Genetic variants in inflammation pathway genes and asthma in glioma susceptibility. Neuro Oncol (2010) 1.15
Central nervous system cancers. J Natl Compr Canc Netw (2011) 1.13
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol (2010) 1.12
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol (2015) 1.11
Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. Int J Radiat Oncol Biol Phys (2008) 1.10
Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol (2006) 1.08
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol (2009) 1.07
Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum (2005) 1.06
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol (2014) 1.06
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol (2006) 1.02
Diffusely infiltrative low-grade gliomas in adults. J Clin Oncol (2006) 1.01
Advances in molecular therapies in patients with brain tumors. Cancer Control (2003) 1.00
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. Neuro Oncol (2013) 1.00
Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro Oncol (2002) 0.99
Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys (2013) 0.99
Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget (2014) 0.98
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol (2004) 0.98
Neurologic complications of cancer and its treatment. Curr Oncol Rep (2010) 0.97
Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev Anticancer Ther (2007) 0.95
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol (2006) 0.95
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol (2009) 0.94
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res (2012) 0.94
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol (2009) 0.94
The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol (2009) 0.93
Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol (2012) 0.93
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol (2008) 0.93
The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients. Cancer (2011) 0.92
Recurrent PIK3CA mutations in rosette-forming glioneuronal tumor. Acta Neuropathol (2011) 0.92
Personal health records as portal to the electronic medical record. J Neurooncol (2014) 0.91
Clinical utility of the MDASI-BT in patients with brain metastases. J Pain Symptom Manage (2008) 0.90
Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. Neuro Oncol (2004) 0.89
Risk factors for fatigue severity in primary brain tumor patients. Cancer (2010) 0.89
Clinical course of adult patients with ependymoma: results of the Adult Ependymoma Outcomes Project. Cancer (2011) 0.89
Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. J Neurooncol (2013) 0.89
Anaplastic oligodendroglial tumors: a tale of two trials. J Clin Oncol (2006) 0.89
Congruence of primary brain tumor patient and caregiver symptom report. Cancer (2012) 0.88
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol (2008) 0.88
Glioblastoma. Handb Clin Neurol (2012) 0.88
Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma (2012) 0.87
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol (2011) 0.87
ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features--correlation of clinical improvement with tumor response. Cancer Invest (2004) 0.87
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. J Neurooncol (2010) 0.87
Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients. Cancer (2010) 0.86
Liver-derived extracellular matrix as a biologic scaffold for acute vocal fold repair in a canine model. Laryngoscope (2009) 0.86
Predictors of survival among older adults with ependymoma. J Neurooncol (2011) 0.86
Practical strategies for management of fatigue and sleep disorders in people with brain tumors. Neuro Oncol (2012) 0.85
Gamma-radiation sensitivity and polymorphisms in RAD51L1 modulate glioma risk. Carcinogenesis (2010) 0.85
Neurologic complications of non-Hodgkin's lymphoma. Curr Hematol Malig Rep (2006) 0.85
Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. J Neurooncol (2012) 0.84
Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007. Neuroepidemiology (2012) 0.84
Seizure risk in brain tumor patients with conversion to generic levetiracetam. J Neurooncol (2009) 0.84
Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathol (2013) 0.84
Validation of the Mishel's uncertainty in illness scale-brain tumor form (MUIS-BT). J Neurooncol (2012) 0.83
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. Neuro Oncol (2013) 0.83
Treating recurrent glioblastoma: an update. CNS Oncol (2015) 0.83
Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis. J Neurooncol (2013) 0.83
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma. Int J Radiat Oncol Biol Phys (2010) 0.83
Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors. J Neurooncol (2011) 0.83